| Added by | standudu |
|---|---|
| Group name | EquipeCTCS |
| Item Type | Journal Article |
| Title | Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohort |
| Creator | Grinda et al. |
| Author | Thomas Grinda |
| Author | Alison Antoine |
| Author | William Jacot |
| Author | Paul-Henri Cottu |
| Author | Jean-Sébastien Frenel |
| Author | Audrey Mailliez |
| Author | Florence Dalenc |
| Author | Anthony Goncalves |
| Author | Florian Clatot |
| Author | Marie-Ange Mouret Reynier |
| Author | Christelle Levy |
| Author | Jean-Marc Ferrero |
| Author | Isabelle Desmoulins |
| Author | Lionel Uwer |
| Author | Thierry Petit |
| Author | Christelle Jouannaud |
| Author | Monica Arnedos |
| Author | Michaël Chevrot |
| Author | Coralie Courtinard |
| Author | Olivier Tredan |
| Author | Etienne Brain |
| Author | David Pérol |
| Author | Barbara Pistilli |
| Author | Suzette Delaloge |
| Abstract | BACKGROUND: Early metastatic relapse of triple-negative breast cancer (mTNBC) after anthracyclins and/or taxanes based (A/T) primary treatment represents a highly aggressive cancer situation requiring urgent characterisation and handling. Epidemio-Strategy-Medico-Economical-Metastatic Breast Cancer (ESME-MBC) database, a multicenter, national, observational cohort (NCT03275311) provides recent data on this entity. METHODS: All ESME patients diagnosed between 2008 and 2020 with mTNBC occurring as a relapse after a systemic neoadjuvant/adjuvant taxane and/or anthracycline-based chemotherapy were included. Early relapses were defined by a metastatic diagnosis up to 12 months of the end of neo/adjuvant A/T chemotherapy. We assessed overall survival (OS) and progression-free-survival under first-line treatment (PFS1) by early versus late relapse (?12 months). RESULTS: Patients with early relapse (N = 881, 46%) were younger and had a larger tumour burden at primary diagnosis than those with late relapses (N = 1045). Early relapse rates appeared stable over time. Median OS was 10.1 months (95% CI 9.3-10.9) in patients with early relapse versus 17.1 months (95% CI 15.7-18.2) in those with late relapse (adjusted hazard-ratio (aHR): 1.92 (95% CI 1.73-2.13); p < 0.001). The median PFS1 was respectively 3.1 months (95% CI 2.9-3.4) and 5.3 months (95% CI 5.1-5.8); (aHR: 1.66; [95% CI 1.50-1.83]; p < 0.001). Among early relapsed patients, a higher number of metastatic sites, visceral disease but not treatment types, were independently associated with a poorer OS. CONCLUSION: These real-world data provide strong evidence on the dismal prognosis, higher treatment resistance and major unmet medical need associated with early relapsed mTNBC. Database registration: clinicaltrials.gov Identifier NCT032753. |
| Publication | European Journal of Cancer (Oxford, England: 1990) |
| Volume | 189 |
| Pages | 112935 |
| Date | 2023-08 |
| Journal Abbr | Eur J Cancer |
| Language | eng |
| DOI | 10.1016/j.ejca.2023.05.023 |
| ISSN | 1879-0852 |
| Library Catalog | PubMed |
| Extra | PMID: 37385070 |
| Tags | Antibiotics, Antineoplastic, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Chronic Disease, clinic, ESME cohort, Female, Humans, Neoplasm Recurrence, Local, Prognosis, Progression-Free Survival, Real-world data, Triple Negative Breast Neoplasms, Triple-negative breast cancer |
| Date Added | 2023/10/16 - 15:10:44 |
| Date Modified | 2023/10/16 - 17:27:15 |
| Notes and Attachments | PubMed entry (Attachment) |
Institut de Recherche en Cancérologie de
